Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

A national resource for tomorrow’s treatments – Karolinska ATMP Center is now inaugurated

With a clear message of hope for the future and a powerful spirit of collaboration, the Karolinska ATMP Center in Flemingsberg was inaugurated at the end of August. The center is a collaboration between Karolinska Institutet and Karolinska University Hospital and will serve as a national resource for the production of advanced therapies (ATMPs), where research, clinical trials, and treatments work seamlessly together to deliver groundbreaking therapies to patients.

Meetings That Shape the Future: Flemingsberg Science at Almedalen

In June this year, the foundation took part in the annual Almedalen Week, the world’s largest democratic meeting place for everyone who wants to join the discussions on current societal issues. This year, we had a special focus on Life Science, an area and cluster that has long been a natural part of Flemingsberg, and which is now growing stronger than ever.

Meet us at NLSDays

In the south of Stockholm you’ll find Flemingsberg, home to a vibrant life science cluster that’s rapidly emerging as an attractive location for life science companies. Here, academia, business and society form a dynamic ecosystem, fueling innovation and growth. And with more companies establishing and collaborations further deepening, the opportunity to expand and invest have never been greater. This year, we are therefore participating in NLSDays in Gothenburg, where we will showcase Flemingsberg's unique strengths and invite more stakeholders to become part of our thriving life science environment.